Newly Released Free, On-Demand CE!

Between a Rock and a Hard Plaque: The Relationship Between LDL-C and ASCVD Risk and Improving Patient Outcomes with PCSK9 Inhibitors

Pharmacists can bridge the gap in ASCVD care with lipid screening, optimization of LDL-C lowering medication therapy, and improving medication adherence. In this program, experts will review updated guideline recommendations for ASCVD risk assessment and treatment; explore statin and nonstatin medications including current and emerging PCSK9 inhibitors; describe strategies for overcoming barriers to achieving LDL-C thresholds; and expand on strategies for increased patient engagement and shared decision-making to optimize outcomes.

We invite you to share this free educational activity with your colleagues.

Featuring...

Joseph Saseen

PharmD, FASHP, MNLA, BCPS, BCACP, Activity Chair

 Associate Dean for Clinical Affairs, Professor, Department of Clinical Pharmacy; Professor, Department of Family Medicine 
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus 
Aurora, Colorado

Bruce A. Warden

PharmD, BCPS, CLS, FNLA, FASPC

Clinical Pharmacist, General Cardiology 
Knight Cardiovascular Institute, Oregon Health & Science University
Portland, Oregon

Target Audience

This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, specialty pharmacies, ambulatory clinics, and community settings who manage patients at high risk for ASCVD or who have clinical ASCVD. 

Learning Objectives

• Analyze the role of LDL-C in ASCVD and the importance of achieving LDL-C thresholds to reduce the risk of ASCVD events.

• Prioritize lipid screening and risk stratification for patients at high risk for ASCVD and with clinical ASCVD, including patients with heterozygous familial hypercholesterolemia, at-risk populations, and patients with high unmet needs. 

• Examine benefits and risks of current and emerging LDL-C lowering pharmacotherapies. 

• Apply current guideline-based recommendations to the treatment of patients at high risk for ASCVD and with clinical ASCVD who are eligible for nonstatin therapies including PCSK9 inhibitors.  

Agenda

Welcome and Introductions
Joseph Saseen
 

Overview of Atherosclerosis

Bruce A. Warden
 

Evidence-based Management of Hypercholesterolemia  

Joseph Saseen
 

Statin and Nonstatin Medications

Joseph Saseen
 

Achieving Recommended LDL-C Thresholds to Reduce ASCVD Event Risk

Bruce A. Warden
 

Faculty Discussion, Questions and Answers

All Faculty

Accredited for CPE

ACPE #: 0204-0000-25-417-H01-P

CE Credit: 1.5 contact hours (0.15 CEUs)

Activity Type: Application-based

Activity Fee: No charge 

Available: February 19, 2026 - February 19, 2027

To receive CE credit, complete the steps below within 60 days of completing the activity.

1. View entire presentation and answer all polling questions.
2. Click "Complete Activity" on the last slide to complete the evaluation.
3. Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.

After the 60-day deadline, ASHP will no longer be able to report credit(s).